235 related articles for article (PubMed ID: 28624153)
1. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
Szender JB; Emmons T; Belliotti S; Dickson D; Khan A; Morrell K; Khan ANMN; Singel KL; Mayor PC; Moysich KB; Odunsi K; Segal BH; Eng KH
Gynecol Oncol; 2017 Sep; 146(3):491-497. PubMed ID: 28624153
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
3. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.
Quan Q; Zhou S; Liu Y; Yin W; Liao Q; Ren S; Zhang F; Meng Y; Mu X
J Obstet Gynaecol Res; 2021 Apr; 47(4):1527-1535. PubMed ID: 33506580
[TBL] [Abstract][Full Text] [Related]
4. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
5. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
[TBL] [Abstract][Full Text] [Related]
6. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
7. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
8. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
[TBL] [Abstract][Full Text] [Related]
9. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
10. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
11. Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer.
Nasioudis D; Byrne M; Ko EM; Haggerty AF; Cory L; Giuntoli Ii RL; Kim SH; Latif NA
Int J Gynecol Cancer; 2021 Dec; 31(12):1579-1583. PubMed ID: 34702746
[TBL] [Abstract][Full Text] [Related]
12. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
Gasimli K; Braicu EI; Richter R; Chekerov R; Sehouli J
Ann Surg Oncol; 2015 Aug; 22(8):2729-37. PubMed ID: 25672560
[TBL] [Abstract][Full Text] [Related]
14. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
15. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
16. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
18. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
19. Impact of ascites on the perioperative course of patients with advanced ovarian cancer undergoing extensive cytoreduction: results of a study on 119 patients.
Feldheiser A; Braicu EI; Bonomo T; Walther A; Kaufner L; Pietzner K; Spies C; Sehouli J; Fotopoulou C
Int J Gynecol Cancer; 2014 Mar; 24(3):478-87. PubMed ID: 24463641
[TBL] [Abstract][Full Text] [Related]
20. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.
Peiretti M; Zanagnolo V; Aletti GD; Bocciolone L; Colombo N; Landoni F; Minig L; Biffi R; Radice D; Maggioni A
Gynecol Oncol; 2010 Nov; 119(2):259-64. PubMed ID: 20800269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
